Figure 1From: Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trialsSCr changes in Phase 3 studies. (A) Mean (±SE) change from baseline in SCr (mg/dl) across the Phase 3 program (0 to 12 months). (B) SCr outliers during tofacitinib 5 mg BID treatment. (C) SCr outliers during tofacitinib 10 mg BID treatment.Back to article page